2016 Harrington Fellow
Dr. Abbott obtained graduated Phi Beta Kappa from the University of Virginia and then matriculated into the Medical Scientist Training Program at the Vanderbilt University School of Medicine.
Upon graduating with his M.D. and Ph.D., Dr. Abbott undertook clinical training in Anatomic Pathology at the Brigham and Women’s Hospital before further scientific training in the laboratory of Dr. Lewis Cantley at Harvard Medical School. He is a member of the American Society of Clinical Investigation and has been awarded the Dolph Adams Award from the Society of Leukocyte Biology.
He currently serves as the Arline H. and Curtis F. Garvin Professor of Medicine, Professor of Pathology and Director of the Medical Scientist Training Program at the Case Western Reserve University School of Medicine in Cleveland, Ohio. He also serves as the co-chair of the Burroughs Wellcome Career Award for Medical Scientists.
Dr. Abbott’s scientific work aims to identify and validate novel pharmaceutical targets in genetic inflammatory disease. This work has identified the kinase RIPK2 as a key nodal point in Rheumatoid Arthritis, Crohn’s disease and Ulcerative Colitis and has further partnered with pharmaceutical partners to develop clinical inhibitors of RIPK2.
Further work identified and validated Gasdermin D as a novel target in inflammasome-driven disease (such as Sepsis) and also identified the first direct chemical inhibitor of Gasdermin D. The overarching goal of this work is to identify novel pharmaceutical targets in these high morbidity, difficult to treat diseases.